Tuberculosis infection and stillbirth in Ethiopia—A prospective cohort study

John Walles1,2*, Laura García Otero3,4,5, Fregenet Tesfaye1,6, Asmamaw Abera7, Marianne Jansson8, Taye Tolea Balcha1,6, Erik Sturegård1,9, Niclas Winqvist10, Stefan R. Hansson11,12, Per Björkman1,13

1 Clinical Infection Medicine, Department of Translational Medicine, Lund University, Malmö, Sweden, 2 Department of Infectious Diseases, Central Hospital, Kristianstad, Sweden, 3 Fetal Medicine Research Center, BCNatal—Barcelona Center for Maternal-Fetal and Neonatal Medicine, University of Barcelona, Barcelona, Spain, 4 Institut Clinic de Ginecologia, Obstetricia i Neonatologia (ICGON), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain, 5 Universitat de Barcelona, and Centre for Biomedical Research on Rare Diseases (CIBER-ER), University of Barcelona, Barcelona, Spain, 6 Ammaer Hansen Research Institute, Addis Ababa University, Addis Ababa, Ethiopia, 7 Ethiopia Institute of Water Resources, Addis Ababa University, Addis Ababa, Ethiopia, 8 Medical Microbiology, Department of Laboratory Medicine, Lund University, Lund, Sweden, 9 Clinical Microbiology, Division of Laboratory Medicine, Lund, Sweden, 10 Skåne Regional Office for Infectious Disease Control and Prevention, Malmö, Sweden, 11 Division of Obstetrics and Gynecology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 12 Skåne University Hospital, Lund, Sweden, 13 Department of Infectious Diseases, Skåne University Hospital, Malmö, Sweden

* John.Walles@med.lu.se

Abstract

Background

Tuberculosis is among the leading causes of death among infectious diseases. Regions with a high incidence of tuberculosis, such as sub-Saharan Africa, are disproportionately burdened by stillbirth and other pregnancy complications. Active tuberculosis increases the risk of pregnancy complications, but the association between latent tuberculosis infection (LTBI) and pregnancy outcomes is unknown. We explored the effect of latent tuberculosis infection on the risk of stillbirth in women attending antenatal care clinics in Ethiopia, a country with >170 000 annual cases of active tuberculosis.

Method

Pregnant women were enrolled from antenatal care at three health facilities in Adama, Ethiopia, during 2015–2018, with assessment for previous and current active tuberculosis and testing for LTBI using QuantiFERON-TB-GOLD-PLUS. Proportions of stillbirth (≥20 weeks of gestation) and neonatal death (<29 days of birth) were compared with respect to categories of maternal tuberculosis infection (tuberculosis-uninfected, LTBI, previous-, and current active tuberculosis). Multivariable logistic regression was performed for stillbirth.

Results

Among 1463 participants enrolled, the median age was 25 years, 10.2% were HIV-positive, 34.6% were primigravidae, and the median gestational age at inclusion was 18 weeks. Four
were diagnosed with active tuberculosis during pregnancy, 68 (4.6%) reported previous treatment for active tuberculosis, 470 (32.1%) had LTBI, and 921 (63.0%) were tuberculosis-uninfected. Stillbirth was more frequent in participants with LTBI compared to tuberculosis-uninfected participants, although not reaching statistical significance (19/470, 4.0% vs 25/921, 2.7%, adjusted [for age, gravidity and HIV serostatus] odds ratio 1.38, 95% confidence interval 0.73–2.57, p = 0.30). Rates of neonatal death (5/470, 1.1% vs 10/921, 1.1%) were similar between these categories.

Conclusion
Latent tuberculosis infection was not significantly associated with stillbirth or neonatal death in this cohort. Studies based on larger cohorts and with details on causes of stillbirth, as well as other pregnancy outcomes, are needed to further investigate this issue.

Introduction
Sub-Saharan Africa carries a disproportionately high burden of maternal mortality, stillbirth, and neonatal death [1–3]. Recent multinational studies have reported that infectious diseases may contribute to 25–60% of stillbirths and half of neonatal deaths in this world region [4,5]. Pregnant women have increased susceptibility to infectious diseases due to transient physiological immune modulations [6]. In addition, several infectious diseases, such as HIV and malaria, can contribute to adverse pregnancy outcomes [7].

Apart from high rates of maternal mortality, stillbirth and neonatal deaths, sub-Saharan Africa also has a high incidence of TB [8]. TB is among the leading infectious causes of morbidity and mortality, globally accounting for more than 1.5 million deaths in 2020 (8). The role of tuberculosis (TB) in the context of pregnancy is debated [9,10]. Compared to other world regions, women living in sub-Saharan Africa have a relatively increased risk of active TB; this has been associated with higher HIV prevalence among women [11]. In addition, it is possible that pregnancy could be involved in this phenomenon, as two register-based studies in Sweden and the United Kingdom have indicated increased incidence of active TB in connection to pregnancy [12,13]. Active TB occurs in around 200 000 pregnant women annually [14] and is a major cause of maternal mortality, contributing to nearly one fourth of non-obstetric maternal deaths in autopsy studies from sub-Saharan Africa [15–18]. Furthermore, active TB has been associated with adverse pregnancy outcomes, including intrauterine growth restriction, stillbirth and perinatal mortality and morbidity [9,10,19–21]. Whether latent TB infection (LTBI), a common condition that is estimated to occur in > 25% of the world population [22], has an impact on pregnancy outcomes has not previously been investigated.

The mechanisms leading to TB-related pregnancy complications are not fully elucidated. Possibly, systemic inflammation, which accompanies active TB and is implicated in the pathogenesis of various pregnancy complications [7], may be involved in these phenomena. For the current study, we hypothesized that LTBI may also be associated with adverse pregnancy outcomes.

In this study, we aimed to assess the effect of LTBI on stillbirth and neonatal death in women screened for active and latent TB infection during pregnancy in Ethiopia.
Methods
Study setting and procedure
This study was based on a prospective cohort of women attending antenatal care (ANC) in Adama, Ethiopia, during 2015–2018, with follow-up until 4 years after delivery [23] (ClinicalTrials.gov identifier: NCT03305991). The health facilities (Adama Hospital Medical College, and Adama and Geda Health Centres) provide TB and HIV care as well as antenatal and obstetric care, and are localized in urban Adama, a city with approximately 300,000 inhabitants in central Ethiopia. Pregnant women were eligible for inclusion at the first ANC visit for their current pregnancy after providing informed consent. At inclusion, participants were interviewed on socioeconomic and demographic characteristics, medical and obstetric history, and details of the current pregnancy. Physical examination was performed. Gestational age at inclusion was determined based on record of last menstrual period, fundal height and/or ultrasound according to clinical routines. Venous blood for LTBI testing was obtained, using QuantiFERON TB GOLD PLUS (QFT) [24]. HIV testing was performed according to Ethiopian guidelines [25]. Participants showing symptoms or signs suggestive of active TB, as well as all HIV-positive participants (irrespective of clinical manifestations), were asked to provide two morning sputum samples for microbiological analysis of Mycobacterium tuberculosis, using smear microscopy, GeneXpert MTB/RIF and liquid culture. Ethiopian guidelines currently recommend symptom-based screening for active TB during routine antenatal care [26]. Diagnosis of active TB could also be based on clinical criteria according to national guidelines [26]. Similar investigations were conducted for study participants presenting symptoms suggestive of active TB during follow-up. Up to 3 follow-up visits were scheduled during pregnancy, as well as 6 weeks after delivery, for assessment of pregnancy outcome. Participants not returning for study visits were traced by phone; in case they had moved out of the uptake area, data on stillbirth and neonatal death were collected through phone interviews.

LTBI was defined as QFT $\geq0.35$ IU/ml in both or either antigen preparation in the assay [27], in the absence of active TB and/or previous history of active TB. Study participants with QFT $<0.35$ IU/ml in both antigen preparations and without active TB nor previous history of active TB were classified as TB-uninfected. Spontaneous abortion was defined as intrauterine demise before 20 weeks of gestation, and stillbirth was defined as death between 20 weeks of gestation and delivery, or on the day of delivery [28]. Neonatal death was defined as death within the first 28 days after birth, excluding reasons unrelated to pregnancy [29].

Participants without QFT results, and without past or current active TB, could not be categorized with regard to TB infection status, and were therefore excluded, as were those reporting induced termination of pregnancy, those with twin pregnancies, and those who did not return for a physical study visit after delivery to ascertain pregnancy outcome. However, study participants who reported foetal or neonatal death at phone contact after delivery (despite not returning for the scheduled post-delivery study visit) were included. Study participants with repeated pregnancies during follow-up were retained in the cohort, but only their ongoing pregnancies at inclusion were considered for the current study.

Statistical analysis
The primary outcome was stillbirth. Neonatal death, caesarean section, and hospitalization $\geq24$ hours in connection to delivery were considered as secondary outcomes. Rates of the separate outcomes were compared with respect to TB infection category in multivariable logistic regression (for outcomes with crude associations with TB category reaching $p<0.20$), with adjustment for maternal age (because of its association with LTBI status [23], gravidity and
HIV serostatus (because of its effect on pregnancy complications) [22]. Maternal education, marital status, and socio-economic characteristics (number of rooms in residence, availability of electricity and latrine in the household) were included in separate sensitivity analyses for each outcome, to control for residual confounding. Cases were excluded from analyses if data was missing on one or more variables included in the respective model. Statistical analysis was performed using R, version 5.3.1 [30].

Ethical considerations
The study was approved by the ethical review committees of Lund University, Sweden and the Ministry of Science and Technology, Addis Ababa, Ethiopia. Written informed consent was obtained from all study participants prior to enrolment in the study, on behalf of themselves and their offspring. Study participants were screened for active TB based on symptoms and clinical signs at all study visits, and treatment for active TB was provided at the respective health facility. Prophylactic treatment for LTBI is recommended only for young children with household TB exposure, and people living with HIV [26], and testing for LTBI is currently not recommended in any situation. Since neither testing nor treatment for LTBI is recommended in pregnant women in the Ethiopian TB Program [26], QFT results were not communicated to participants or healthcare providers.

Results
Participant characteristics
Among 2085 pregnant women included in the cohort, 228 could not be classified with regard to LTBI (QFT results missing, Fig 1). Following the time of scheduled delivery, 1456 had a physical study visit, 169 were reached by telephone, and 232 could not be contacted after delivery. Among those reached by telephone, 30 reported either intrauterine or neonatal death; these were retained in the study together with those with a physical visit after delivery. Among these 1486 study participants, 21 were excluded because of twin pregnancy, and two because of medically induced termination of pregnancy (one because of anencephaly), leaving 1463 for analysis.

Study participants that could not be classified regarding TB infection were excluded, their characteristics were similar to those remaining in the study, as previously reported [23]. Study participants that did not return for a physical visit could still be retained if they reported spontaneous abortion, stillbirth or neonatal death on telephone contact. Participants reporting medically induced termination of pregnancy as well as twin pregnancies were excluded.

Compared to participants remaining for analysis, the 371 participants excluded due to lack of postpartum study visit were younger (24.1 vs 25.2 years, \( p < 0.001 \)), more frequently primigravidae (45.8% vs 34.5%, \( p < 0.001 \)), and were less likely to be HIV-positive (4.0% vs 10.2% \( p < 0.001 \)) (Table 1). The distribution with regard to TB infection category was similar between included and excluded study participants (TB uninfected 65.8% vs 62.9%) (Table 1).

At inclusion, median age was 25 years (interquartile range [IQR] 22–28), with median gestational age 18 weeks (IQR 14–21) (Table 1). Of 150 (10.3%) HIV-positive participants, 17 (11.3%) were diagnosed with HIV in connection to the current pregnancy, 108 (72.0%) were on antiretroviral therapy for \( \geq 3 \) months, and 87 (58.0%) had plasma HIV RNA levels <150 copies/mL. Five-hundred-five participants (34.5%) were primigravidae. The median gestational age at delivery was 40 weeks (IQR 38–42).

Four (0.3%) women were diagnosed with active TB during (3 pulmonary TB [2 HIV-positive, 1 HIV-negative], 1 TB pleuritis [HIV-negative]), and 68 (4.6%) had received treatment for active TB before pregnancy. LTBI was detected in 470 (32.1%) participants, and 921
(63.0%) were classified as TB-uninfected. A greater proportion of participants with LTBI were >25 years of age compared to TB-uninfected participants (52.8% vs 36.7%, p<0.001), and reported previous pregnancies more frequently (71.5% vs 61.3%, p<0.001) (Table 1).
Table 1. Study participant characteristics and pregnancy outcomes by TB infection status.

| Characteristics          | TB-uninfected<sup>1</sup> N = 921 | LTBI<sup>2</sup> N = 470 | Previous active TB<sup>3</sup> N = 68 | Active TB diagnosed during pregnancy<sup>4</sup> (n = 4) | Excluded<sup>5</sup> N = 371 |
|--------------------------|-----------------------------------|--------------------------|---------------------------------------|------------------------------------------------|--------------------------|
| DEMOGRAPHIC              | N %                               | N %                      | N %                                   | N %                                           | N %                      |
| Age (years)              | Median, IQR                        |                          |                                       |                                               |                          |
|                          | 25 22–27                           | 26 23–28                 | 26 23–30                              | 24 22–26                                      | 24 20–27                 |
|                          | < 21 183 19.9                       | 53 11.3                  | 9 13.2                                | 0 0                                           | 102 27.5                 |
|                          | 21–25 400 43.4                     | 168 35.7                 | 20 29.4                               | 3 75.0                                        | 140 37.7                 |
|                          | 26–30 278 30.2                     | 192 40.9                 | 29 42.6                               | 1 25.0                                        | 106 28.6                 |
|                          | > 30 60 6.5                         | 56 11.9                  | 10 14.7                               | 0 0                                           | 21 5.7                   |
|                          | Unknown 0 0                         | 1 0.2                    | 0 0                                   | 0 0                                           | 2 0.5                    |
| Marital status           | Single 27 2.9                       | 11 2.3                   | 4 5.9                                 | 0 0                                           | 11 3.0                   |
|                          | Married 882 95.8                    | 456 97.0                 | 64 94.1                               | 4 100.0                                       | 352 94.9                 |
|                          | Divorced 9 1                        | 2 0.4                    | 0 0                                   | 0 0                                           | 4 1.1                    |
|                          | Widow 2 0.2                         | 0 0                      | 0 0                                   | 0 0                                           | 1 0.3                    |
|                          | Unknown 1 0.1                       | 1 0.2                    | 0 0                                   | 0 0                                           | 3 0.8                    |
| Education                | Illiterate 95 10.3                  | 65 13.8                  | 17 25.0                               | 1 25.0                                        | 50 13.5                  |
|                          | < 6 grades 201 21.8                 | 84 17.9                  | 6 8.8                                 | 0 0                                           | 75 20.2                  |
|                          | 6–12 grades 536 58.2                | 267 56.8                 | 34 50.0                               | 1 25.0                                        | 200 53.9                 |
|                          | Higher education 89 9.7             | 53 11.3                  | 11 16.2                               | 2 50.0                                        | 44 11.9                  |
|                          | Unknown 0 0                         | 1 0.2                    | 0 0                                   | 0 0                                           | 2 0.5                    |
| Rooms in residence       | 1 511 55.5                          | 232 49.4                 | 31 45.6                               | 3 75.0                                        | 222 59.8                 |
|                          | ≥ 2 407 44.2                        | 235 50.0                 | 37 54.4                               | 1 25.0                                        | 145 39.1                 |
|                          | Unknown 3 0.3                       | 3 0.6                    | 0 0                                   | 0 0                                           | 4 1.1                    |
| Electricity in residence | No 38 4.1                           | 20 4.3                   | 5 7.4                                 | 0 0                                           | 11 3.0                   |
|                          | Yes 878 95.3                        | 445 94.7                 | 62 91.2                               | 4 100.0                                       | 357 96.2                 |
|                          | Unknown 5 0.5                       | 5 1.1                    | 1 1.5                                 | 0 0                                           | 4 1.1                    |
| Latrine in residence     | No 50 5.4                           | 36 7.7                   | 5 7.4                                 | 0 0                                           | 15 4.0                   |
|                          | Yes 868 94.2                        | 430 91.5                 | 63 92.6                               | 4 100                                         | 354 95.4                 |
|                          | Unknown 3 0.3                       | 4 0.9                    | 0 0                                   | 0 0                                           | 2 0.5                    |
| OBSTETRIC                | First pregnancy                    |                          |                                       |                                               |                          |
|                          | No 565 61.3                         | 336 71.5                 | 52 76.5                               | 1 25.0                                        | 198 53.4                 |
|                          | Yes 352 38.2                        | 134 28.5                 | 16 23.5                               | 3 75.0                                        | 170 45.8                 |
|                          | Unknown 4 0.4                       | 0 0                     | 0 0                                   | 0 0                                           | 3 0.8                    |
| Gestational age at inclusion (weeks) | Median (IQR) |                          |                                       |                                               |                          |
|                          | 18 14–20                           | 18 14–22                 | 18 13–20                              | 14 11–14                                      |                          |
|                          | < 14 143 15.5                       | 84 17.9                  | 18 26.5                               | 2 50.0                                        | 57 15.4                  |
|                          | 14–27 555 60.3                      | 266 56.6                 | 40 58.8                               | 2 50.0                                        | 208 56.1                 |
|                          | > 27 31 3.4                         | 17 3.6                   | 3 4.4                                 | 0 0                                           | 29 7.8                   |
|                          | Unknown 192 20.8                    | 103 21.9                 | 7 10.3                                | 0 0                                           | 77 20.8                  |
| HIV-RELATED              | HIV negative 845 91.7              | 426 90.3                 | 40 58.8                               | 2 50.0                                        | 356 96.0                 |

(Continued)
No maternal deaths were observed among the included women. In total, 64 (4.4%) pregnancies resulted in intrauterine demise, among which 11 (17.2%) were classified as spontaneous abortions and 47 (73.4%) as stillbirths, and 6 deaths (9.4%) occurred at an unknown gestational age (Table 2). Fifteen neonatal deaths were observed (1.0%). One-hundred-sixty-seven (11.4%) and 22 (1.5%) women delivered by caesarean section and instrumental delivery, respectively, and 110 (7.5%) were hospitalized for ≥24 hours in connection to delivery. Three participants reported foetal congenital malformation, these pregnancies resulted in stillbirth.

### Stillbirth and neonatal death with regard to maternal LTBI

Rates of spontaneous abortion (5/470, 1.1% vs 5/921, 0.5%) and stillbirth (19/470, 4.0% vs 25/921 (2.7%) were slightly higher in participants with LTBI compared to TB-uninfected participants. Stillbirth was not significantly associated with maternal LTBI in simple (OR 1.51, p = 0.18) or multivariable logistic regression analysis adjusting for HIV status, age and gravidity (AOR 1.38, 95% CI 0.73–2.57, p = 0.30) (Table 3). In sensitivity analysis with additional adjustment for maternal education and marital status, number of rooms and presence of electricity and latrine in the household, similar results were obtained (AOR 1.40, 95% CI 0.73–2.63, p = 0.30, S1 Table).

The proportions of neonatal death (1.1% vs 1.1%) were similar among women with LTBI compared to those without TB infection. Similar findings were obtained for rates of hospitalization (7.7% vs 7.7%) and caesarean section (11.9% vs 11.5%).

---

**Table 1.** (Continued)

| Characteristics                  | TB-uninfected<sup>1</sup> N = 921 | LTBI<sup>2</sup> N = 470 | Previous active TB<sup>3</sup> N = 68 | Active TB diagnosed during pregnancy<sup>4</sup> (n = 4) | Excluded<sup>5</sup> N = 371 |
|----------------------------------|-----------------------------------|---------------------------|--------------------------------------|--------------------------------------|---------------------------|
| HIV positive                     | 76                                | 8.3                       | 44                                   | 9.4                                  | 28                        | 41.2                      | 2                          | 50.0                    | 15                        | 4.0                      |
| ART duration (months)<sup>6</sup> |                                   |                           |                                      |                                      |                           |                           |                           |                         |                           |
| Median (IQR)                     |                                   |                           |                                      |                                      |                           |                           |                           |                         |                           |
| HIV diagnosis<sup>5</sup>        |                                   |                           |                                      |                                      |                           |                           |                           |                         |                           |
| During current pregnancy         | 10                                | 13.2                      | 6                                    | 13.6                                 | 1                         | 3.6                       | 0                          | 0                       | 2                          | 13.3                      |
| Before current pregnancy         | 56                                | 73.7                      | 32                                   | 72.7                                 | 25                        | 89.3                      | 2                          | 100                     | 10                         | 66.7                      |
| Unknown                          | 10                                | 13.2                      | 6                                    | 13.6                                 | 2                         | 7.1                       | 0                          | 9                       | 3                          | 20.0                      |
| ART naïve or <3 months           | 36                                | 5–61                      | 34                                   | 14–49                                | 58                        | 35–89                     | 51                         | 27–75                   | 44                         | 16–76                     |
| ART ≥3 months                    | 51                                | 67.1                      | 30                                   | 68.2                                 | 25                        | 89.3                      | 2                          | 100.0                   | 10                         | 66.7                      |
| Unknown                          | 10                                | 13.2                      | 6                                    | 13.6                                 | 2                         | 6.9                       | 0                          | 0                       | 3                          | 20.0                      |
| Viral load (copies/ml)<sup>6</sup>|                                   |                           |                                      |                                      |                           |                           |                           |                         |                           |
| <150                             | 39                                | 51.3                      | 29                                   | 65.9                                 | 18                        | 64.3                      | 1                          | 50.0                    | 8                          | 53.3                      |
| 150–999                          | 5                                 | 6.6                       | 1                                    | 2.3                                  | 1                         | 3.6                       | 1                          | 50.0                    | 1                          | 6.7                       |
| ≥1000                            | 23                                | 30.3                      | 30                                   | 18.2                                 | 1                          | 3.6                       | 0                          | 0                       | 4                          | 26.7                      |
| Unknown                          | 9                                 | 11.8                      | 6                                    | 13.6                                 | 8                         | 28.6                      | 0                          | 0                       | 2                          | 13.3                      |

**Abbreviations**

- Tuberculosis (TB), latent TB infection (LTBI), interquartile range (IQR), antiretroviral therapy (ART), millilitre (ml).
- 1. Study participants without past or current active TB and with negative QuantiFERON TB GOLD PLUS reactivity.
- 2. Study participants with positive QuantiFERON TB GOLD PLUS reactivity, without past or current active TB.
- 3. Study participants reporting previous treatment for active TB.
- 4. Study participants diagnosed with active during the pregnancy or within three months of delivery.
- 5. Excluded because of lack of study visit after delivery. In this group, 244 (65.8%) were classified as TB-uninfected, 117 (31.5)% as having LTBI, 9 (2.4%) reported previous active TB and 1 (0.3%) were diagnosed with active TB in connection to pregnancy, respectively.
- 6. Concerning HIV-positive participants only.

https://doi.org/10.1371/journal.pone.0261972.1001
Foetal and neonatal death in participants with past or current active TB

No foetal or neonatal deaths were reported among the four women with active TB during the pregnancy. Among participants with previous treatment for active TB, 3/68 (4.4%) pregnancies resulted in stillbirth (OR 1.65, AOR 1.47, 95% CI 0.33–4.68, p = 0.56, Table 3). Rates of hospitalization (2/68, 2.9%) and caesarean section (4/68, 5.9%) were slightly lower than in TB-uninfected participants. There were no neonatal deaths in this group.

Discussion

In this cohort of Ethiopian pregnant women categorized for TB infection, rates of foetal death were slightly higher among women with LTBI as compared to those without TB infection, but this difference did not reach statistical significance. The risk of reproductive morbidity and mortality is unevenly distributed globally, with 98% of stillbirths occurring in low- and middle-income countries [31]. Poverty and limited access to healthcare contribute to this phenomenon. However, women of African origin immigrating to high-income countries such as Sweden have an increased risk of stillbirth compared to native Swedes [32]. Several factors, including socio-economic conditions, quality of care provided and health-seeking behaviour, may be involved in this phenomenon. In addition, infectious diseases have been proposed to contribute to an excess risk of adverse pregnancy outcome in migrants in high-income countries [33]. In this context, TB infection is of interest,
since it is common in sub-Saharan Africa, and since active TB is a recognized risk factor for adverse pregnancy outcomes [9].

Pregnant women have increased susceptibility to various infectious diseases, which may in turn contribute to pregnancy complications, with variable pathogenetic mechanisms involving placental or foetal invasion as well as systemic inflammatory responses disturbing placental development [7,34–40]. While placental or foetal involvement of TB has been rarely described [41], the mechanisms leading to the majority of TB-associated pregnancy complications are not fully explained.

Interestingly, elevated levels of biomarkers of systemic inflammation have also been reported in persons with LTBI [42–45], and a recent study revealed differences in peripheral blood cytokine profiles among Indian pregnant women with LTBI compared to TB-uninfected women [46]. Furthermore, recent observational studies have suggested associations between LTBI and myocardial infarction and atherosclerosis [47,48], which has been suggested to be linked to chronic low-grade inflammation. These observations led us to hypothesize that low-grade systemic inflammation in people with LTBI might contribute to pregnancy-related disorders as well.

Although we did not find a significant difference in rates of stillbirth with regard to LTBI status in our study population, it is possible that a larger sample size could have revealed such an association. In addition, associations between LTBI and certain types of pregnancy complications may have been missed in the current study, due to restricted sample size and insufficient information to determine specific pregnancy complications and causes of stillbirth among participants.

### Table 3. Crude and adjusted odds ratios for stillbirth (≥20 weeks of gestation) with respect to maternal TB infection category, maternal age, gravidity and HIV-status.

| Characteristic | OR  | 95% CI  | p   | AOR  | 95% CI  | p   |
|----------------|-----|---------|-----|------|---------|-----|
| **TB category** |     |         |     |      |         |     |
| TB uninfected1 | Ref | Ref     | Ref | Ref  | Ref     | Ref |
| LTBI2          | 1.51| 0.81–2.76| 0.18| 1.38 | 0.73–2.57| 0.30|
| Previous active TB3 | 1.65| 0.38–4.85| 0.43| 1.47 | 0.33–4.68| 0.56|
| Current active TB4 | NA | NA     | NA  | NA   | NA     | NA  |
| **Age (years)** |     |         |     |      |         |     |
| <21 | Ref | Ref     | Ref | Ref  | Ref     | Ref |
| 21–25 | 0.56| 0.22–1.47| 0.22| 0.70 | 0.27–1.85| 0.45|
| 26–30 | 1.04| 0.46–2.59| 0.92| 1.55 | 0.62–4.14| 0.36|
| >30 | 2.82| 1.11–7.47| 0.03| 4.54 | 1.55–13.8| 0.006|
| **First pregnancy** |     |         |     |      |         |     |
| Yes | 1.42| 0.78–2.56| 0.24| 2.32 | 1.15–4.64| 0.02|
| No | Ref | Ref     | Ref | Ref  | Ref     | Ref |
| **HIV status** |     |         |     |      |         |     |
| HIV negative | Ref | Ref     | Ref | Ref  | Ref     | Ref |
| HIV positive | 1.28| 0.48–2.87| 0.57| 1.02 | 0.36–2.47| 0.97|

Adjustments were made for maternal age, gravidity and HIV status. Due to missing data on covariates, 11 cases (0.8%) were excluded from multivariable analysis.

Abbreviations: Odds ratio (OR), confidence interval (CI), adjusted odds ratio (AOR), Tuberculosis (TB), latent TB infection (LTBI), caesarean section (CS).

1. Study participants without past or current active TB and with negative QuantiFERON TB GOLD PLUS reactivity.
2. Study participants with positive QuantiFERON TB GOLD PLUS reactivity, without past or current active TB.
3. Study participants reporting previous treatment for active TB.
4. Study participants diagnosed with active during the pregnancy or within three months of delivery.

https://doi.org/10.1371/journal.pone.0261972.t003
Our study participants were recruited at public ANC clinics in a TB-endemic urban uptake area in Ethiopia [23]. All participants were systematically screened for LTBI using a modern interferon-γ release assay. Apart from the limitations mentioned above, nearly 20% of the women did not have a physical post-partum study visit. Although adverse pregnancy outcomes may have been more common in this group, loss to follow-up was distributed similarly with respect to LTBI status and other characteristics; therefore, we consider it unlikely that this led to bias regarding the association between foetal death and LTBI. The total proportion of stillbirths occurring after 28 gestational weeks (including intrapartum deaths) was comparable to estimations for sub-Saharan Africa [31].

Conclusions

In this cohort of pregnant Ethiopian women, LTBI was not significantly associated with stillbirth nor neonatal death. Further studies with larger sample size and ascertainment of other types of pregnancy complications are required to determine whether LTBI is involved in stillbirth or other specific types of adverse pregnancy outcomes.

Supporting information

S1 Checklist.
(DOCX)

S1 Table. Odds ratios for foetal death with respect to maternal TB infection category with broader adjustment. Abbreviations: OR: Odds Ratio CI: Confidence Interval LTBI: Latent Tuberculosis Infection.

S1 File. Raw data.
(XLSX)

Acknowledgments

We extend our gratitude towards the women participating in this study, the staff at our study sites, and Mr Gadissa Merga, Mr Surafel Girma and Ms Yemisrach Alemayehu of the Adama Lund University research team. We also wish to thank Mrs Masresha Getahun for her diligent work with telephone contacts with study participants for tracing and data collection. We are also grateful for the support and assistance from the Adama Regional Laboratory, the Armauer Hansen Research Institute and the Oromia Regional Health Bureau.

Author Contributions

Conceptualization: John Walles, Fregenet Tesfaye, Taye Tolera Balcha, Erik Sturegård, Niclas Winqvist, Stefan R. Hansson, Per Björkman.

Data curation: John Walles, Laura García Otero, Fregenet Tesfaye, Asmamaw Abera, Erik Sturegård, Niclas Winqvist.

Formal analysis: John Walles.

Funding acquisition: John Walles, Stefan R. Hansson, Per Björkman.

Investigation: John Walles, Fregenet Tesfaye, Asmamaw Abera, Per Björkman.

Methodology: John Walles, Asmamaw Abera, Taye Tolera Balcha, Erik Sturegård, Niclas Winqvist, Stefan R. Hansson, Per Björkman.
Project administration: John Walles, Niclas Winqvist, Per Björkman.

Resources: Per Björkman.

Supervision: Taye Tolera Balcha, Niclas Winqvist, Stefan R. Hansson, Per Björkman.

Writing – original draft: John Walles, Asmamaw Abera, Per Björkman.

Writing – review & editing: John Walles, Laura García Otero, Fregenet Tesfaye, Asmamaw Abera, Marianne Jansson, Taye Tolera Balcha, Erik Sturegård, Niclas Winqvist, Stefan R. Hansson, Per BJörkman.

References

1. World Health Organization. Strategies toward ending preventable maternal mortality. 2015.
2. GBD Child Mortality Collaborators. Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. 2016;388(10053):1725–74.
3. Blencowe H, Cousens S, Jassir FB, Say L, Chou D, Mathers C, et al. National, regional, and worldwide estimates of stillbirth rates in 2015, with trends from 2000: A systematic analysis. Lancet Glob Heal. 2016; 4(2):e98–108.
4. Taylor AW, Blau DM, Bassat Q, Onyango D, Kotloff KL, Arifeen SE, et al. Initial findings from a novel population-based child mortality surveillance approach: a descriptive study. Lancet Glob Heal. 2020; 8(7):e909–19. https://doi.org/10.1016/S2214-109X(20)30205-9 PMID: 32562647
5. McClure EM, Saleem S, Goudar SS, Garces A, Whitworth R, Esamai F, et al. Stillbirth 2010–2018: a prospective, population-based, multi-country study from the Global Network. Reprod Health. 2020; 17(Suppl 2):1–9. https://doi.org/10.1186/s12978-020-00991-y PMID: 33256783
6. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and Infection. N Engl J Med. 2014; 23370(5):2211–8.
7. Weckman AM, Ngai M, Wright J, McDonald CR, Kain KC. The impact of infection on placental vascular development and adverse birth outcomes. Front Microbiol. 2019; 10(AUG):1–11. https://doi.org/10.3389/fmicb.2019.01924 PMID: 31507551
8. World Health Organization. Global Tuberculosis Report. Geneva; 2021.
9. Mathad JS, Gupta A. Tuberculosis in Pregnant and Postpartum Women: Epidemiology, Management, and Research Gaps. Clin Infect Dis. 2012; 55(11):1532–49. https://doi.org/10.1093/cid/cis732 PMID: 22942202
10. Miele K, Barmah Morris S, Tepper NK. Tuberculosis in Pregnancy. Obstet Gynecol. 2020; 135(6):1444–53. https://doi.org/10.1097/AOG.0000000000003890 PMID: 32459437
11. Horton KC, Macpherson P, Houben RMGJ, White G, Corbett EL. Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. 2016; 21:1–23.
12. Jonsson J, Kühlmann-Berenzon S, Berggren I, Bruchfeld J. Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden. Eur Respir J. 2019;1901886.
13. Zerden D, Krujisha ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: A national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med. 2012; 185(7):779–84. https://doi.org/10.1164/rcrm.201106-1083OC PMID: 22161161
14. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: An estimate of the global burden of disease. Lancet Glob Heal. 2014; 2(12):e710–6. https://doi.org/10.1016/S2214-109X(14)70330-4 PMID: 25433626
15. Khan M, Pillay T, Moodley JM, Connolly CA. Maternal mortality associated with tuberculosis-HIV-1 co-infection in Durban, South Africa. Aids. 2001; 15(14):1857–63. https://doi.org/10.1097/00002030-200109280-00016 PMID: 11579249
16. García-Basteiro AL, Hurtado JC, Castillo P, Fernandes F, Navarro M, Lovane L, et al. Unmasking the hidden tuberculosis mortality burden in a large post mortem study in Maputo Central Hospital, Mozambique. Eur Respir J. 2019;54(3).
17. Menéndez C, Romagosa C, Ismail MR, Carrilho C, Saute F, Osman N, et al. An autopsy study of maternal mortality in Mozambique: The contribution of infectious diseases. PLoS Med. 2008; 5(2):0220–6. https://doi.org/10.1371/journal.pmed.0050044 PMID: 18288887
18. Ahmed Y, Mwaba P, Chintu C, Grange JM, Ustianowski A, Zumla A. A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: The emergence of tuberculosis as a major non-obstetric cause of maternal death. Int J Tuber Lung Dis. 1999; 3(8):675–80. PMID: 10460099

19. El-Messidi A, Cuzzoz-Shulman N, Spence AR, Abenhaim HA. Medical and obstetric outcomes among pregnant women with tuberculosis: a population-based study of 7.8 million births. Am J Obstet Gynecol. 2016; 215(6):797.e1–797.e6. https://doi.org/10.1016/j.ajog.2016.08.009 PMID: 27530490

20. Bates M, Ahmed Y, Kapata N, Maeruer M, Mwaba P, Zumla A. Perspectives on tuberculosis in pregnancy. Int J Infect Dis. 2015; 32:124–7. https://doi.org/10.1016/j.ijid.2014.12.014 PMID: 25809768

21. Ormerod P. Tuberculosis in pregnancy and the puerperium. Thorax. 2001;(56):494–9. https://doi.org/10.1136/thorax.56.6.494 PMID: 11359968

22. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015; 372(22):2127–35. https://doi.org/10.1056/NEJMra1405427 PMID: 26017823

23. Walles J, Tesfaye F, Jansson M, Balcha TT, Sturegård E, Kefeni M, et al. Tuberculosis infection in women of reproductive age—a cross-sectional study at antenatal care clinics in an Ethiopian city. Clin Infect Dis. 2021; 73(2):203–10. https://doi.org/10.1093/cid/ciaa561 PMID: 32412638

24. König Walles J, Tesfaye F, Jansson M, Balcha TT, Winqvist N, Kefeni M, et al. Performance of Quantiferon-TB gold plus for detection of latent tuberculosis infection in pregnant women living in a tuberculosis- and HIV-endemic setting. PLoS One. 2018; 13(4):1–15.

25. National guidelines for comprehensive HIV prevention, care and treatment. Addis Ababa: Ministry of Health, Federal Democratic Republic of Ethiopia; 2017.

26. National Guidelines for TB, DR-TB and Leprosy in Ethiopia. Addis Ababa: Ministry of Health, Federal Democratic Republic of Ethiopia; 2017.

27. Barcellini L, Borroni E, Brown J, Brunetti E, Campisi D, Castellotti PF, et al. First evaluation of Quantiferon-TB Gold Plus performance in contact screening. Nat Publ Gr [Internet]. 2016; 98104(6):1–8. Available from: https://doi.org/10.1038/srep30617 PMID: 27470684

28. What is Stillbirth? [Internet]. Centers for Disease Control and Prevention. [cited 2020 Oct 13]. Available from: https://www.cdc.gov/nchbddd/stillbirth/facts.html.

29. Lawn JE, Cousens S, Zupan J. 4 Million neonatal deaths: When? Where? Why? Lancet. 2005; 365(9462):891–900. https://doi.org/10.1016/S0140-6736(05)71048-5 PMID: 15752534

30. Core Team, R Foundation for Statistical Computing, Vienna, Austria R: A language and environment for statistical computing, version 3.5.1. 2018.

31. Lawn JE, Blencowe H, Waiswa P, Amouzou A, Mathers C, Hogan D, et al. Stillbirths: Rates, risk factors, and acceleration towards 2030. Lancet. 2016; 387(10018):587–603. https://doi.org/10.1016/S0140-6736(15)00837-5 PMID: 26794078

32. Ekéus C, Cnattingius S, Essén B, Hjern A. Stillbirth among foreign-born women in Sweden. Eur J Public Health. 2011; 21(6):788–92. https://doi.org/10.1093/europub/ckq200 PMID: 21224278

33. Gissler M, Alexander S, Macfarlane A, Small R, Strat-Pedersen B, Zeilitz J, et al. Stillbirths and infant deaths among migrants in industrialized countries. Vol. 88, Acta Obstetricia et Gynecologica Scandinavica. 2009. p. 134–48. https://doi.org/10.1080/00016340802603805 PMID: 19096947

34. Rogerson SJ, Hvid I, Duffy PE, Leke RF, Taylor DW. Malaria in pregnancy: pathogenesis and immunity. Lancet Infect Dis. 2007; 7(2):105–17. https://doi.org/10.1016/S1473-3099(07)70022-1 PMID: 17251081

35. Vermillion MS, Klein SL. Pregnancy and infection: Using disease pathogenesis to inform vaccine strategy. npj Vaccines. 2018;3(1). https://doi.org/10.1038/s41541-017-0043-3 PMID: 29387473

36. Redman CWG, Staff AC, Roberts JM. Syncytiotrophoblast stress in preeclampsia: the convergence point for multiple pathways. Am J Obstet Gynecol. 2021;1–21. https://doi.org/10.1016/j.ajog.2020.09.047 PMID: 33546842

37. Pehrsun C, Mathiesen L, Heno KK, Salanti A, Resende M, Dzikowski R, et al. Adhesion of Plasmodium falciparum infected erythrocytes in ex vivo perfused placental tissue: A novel model of placental malaria. Malar J. 2016; 15(1):1–12. https://doi.org/10.1186/s12936-016-1342-2 PMID: 27230523

38. Quanquin NM, Barres LG, Aliyari SR, Day NT, Gerami H, Fisher SJ, et al. Gravity-dependent associations between interferon response and birth weight in placental malaria. Malar J. 2020 Aug 5; 19(1). https://doi.org/10.1186/s12936-020-03351-0 PMID: 32758231

39. Wedi COO, Kirtley S, Hopewell S, Corrigan R, Kennedy SH, Hemelaira J. Perinatal outcomes associated with maternal HIV infection: A systematic review and meta-analysis. Lancet HIV. 2016; 3(1):e33–48. https://doi.org/10.1016/S2335-3018(15)00207-6 PMID: 26762992

40. Mikyas Y, Aziz N, Harawa N, Gorre M, Neagos N, Nogueira M, et al. Immunologic activation during pregnancy: Serial measurement of lymphocyte phenotype and serum activation molecules in HIV-
infected and uninfected women. J Reprod Immunol. 1997; 33(2):157–70. https://doi.org/10.1016/s0165-0378(97)00018-1 PMID: 9234214

41. Abramowsky CR, Gutman J, Hilinski JA. Mycobacterium tuberculosis infection of the placenta: A study of the early (innate) inflammatory response in two cases. Pediatr Dev Pathol. 2012; 15(2):132–6. https://doi.org/10.2350/11-05-1039-CC.1 PMID: 22260536

42. Huaman MA, Deepe GS Jr., Fichtenbaum CJ. Elevated Circulating Concentrations of Interferon-Gamma in Latent Tuberculosis Infection. Pathog Immun. 2016; 1(2):291. https://doi.org/10.20411/pai.v1i2.149 PMID: 27853753

43. LaVergne S, Umlauf A, McCutchan A, Heaton R, Benson C, Kumarasamy N, et al. Impact of Latent Tuberculosis Infection on Neurocognitive Functioning and Inflammation in HIV-Infected and Uninfected South Indians. J Acquir Immune Defic Syndr. 2020; 84(4):430–6. https://doi.org/10.1097/QAI.0000000000002368 PMID: 32282443

44. Wang S, Li Y, Shen Y, Wu J, Gao Y, Zhang S, et al. Screening and identification of a six-cytokine biomarker for detecting TB infection and discriminating active from latent TB. J Transl Med. 2018; 16(1):1–13. https://doi.org/10.1186/s12967-017-1374-6 PMID: 29316942

45. Estévez O, Anibarro L, Garet E, Pallares Á, Pena A, Villaverde C, et al. Identification of candidate host serum and saliva biomarkers for a better diagnosis of active and latent tuberculosis infection. PLoS One. 2020; 15(7):e0235859. https://doi.org/10.1371/journal.pone.0235859 PMID: 32687494

46. Naik S, Alexander M, Kumar P, Kulkarni V, Deshpande P, Yadana S, et al. Systemic Inflammation in Pregnant Women With Latent Tuberculosis Infection. Front Immunol. 2021; 11(January):1–9. https://doi.org/10.3389/fimmu.2020.587617 PMID: 33584652

47. Huaman MA, De Cecco CN, Bittencourt MS, Ticena E, Kityo C, Isabel B, et al. Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda. Clin Infect Dis. 2021;(October 2019):1–7.

48. Huaman MA, Ticena E, Miranda G, Kryscio RJ, Mugruza R, Aranda E, et al. The Relationship between Latent Tuberculosis Infection and Acute Myocardial Infarction. Clin Infect Dis. 2018; 66(6):886–92. https://doi.org/10.1093/cid/cix910 PMID: 29069328